Mark Stejbach Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Mark Stejbach.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Mark Stejbach. Mark Stejbach is a VP & Chief Commercial Officer in TENGION INC ($TNGN) and a VP and Chief Commercial Offcr in TENGION INC ($TNGN) and a Director in Flexion Therapeutics Inc ($FLXN) and a Chief Commercial Officer in Alkermes plc. ($ALKS) and a SVP/Chief Comm Off, Alks Inc in Alkermes plc. ($ALKS).
Address: C/O TENGION, INC. 2900 POTSHOP LANE, SUITE 100 EAST NORRITON 19403 PA
Companies in which Mark Stejbach is an Insider
Alkermes plc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark Stejbach: SVP/Chief Comm Off, Alks Inc, Chief Commercial Officer
Holdings: 51,837 shares
Current Value: $2,839,112
Latest Transaction: Mar 05 2018
$ALKS Market Capitalization: $8.28B
$ALKS Previous Close: $54.77
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Flexion Therapeutics Inc
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Mark Stejbach: Director
Holdings: 6,551 shares
Current Value: $124,731
Latest Transaction: Jun 12 2020
$FLXN Market Capitalization: $504.85M
$FLXN Previous Close: $19.04
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
TENGION INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Mark Stejbach: VP and Chief Commercial Offcr, VP & Chief Commercial Officer
Holdings: 28,663 shares
Latest Transaction: May 13 2011
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Mark Stejbach
Sentiment: All, ALKS, FLXN, TNGN
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 2020 | FLXN | Flexion Therapeuti ... | Stejbach Mark | Director | Option Exercise | A | 11.88 | 7,000 | 83,160 | 7,000 | |
| Jun 12 2020 | FLXN | Flexion Therapeuti ... | Stejbach Mark | Director | Grant | A | 0.00 | 4,500 | 0 | 6,551 | 2.1 K to 6.6 K (+219.41 %) |
| May 27 2020 | FLXN | Flexion Therapeuti ... | Stejbach Mark | Director | Buy | P | 9.75 | 2,051 | 19,997 | 2,051 | 0 to 2.1 K |
| Jun 21 2019 | FLXN | Flexion Therapeuti ... | Stejbach Mark | Director | Option Exercise | A | 11.74 | 12,500 | 146,750 | 12,500 | |
| Jun 21 2018 | FLXN | Flexion Therapeuti ... | Stejbach Mark | Director | Option Exercise | A | 28.14 | 12,500 | 351,750 | 12,500 | |
| Mar 05 2018 | ALKS | Alkermes plc. | Stejbach Mark | SVP/Chief Comm Off, ... | Option Exercise | M | 0.00 | 2,813 | 0 | 0 | |
| Mar 05 2018 | ALKS | Alkermes plc. | Stejbach Mark | SVP/Chief Comm Off, ... | Option Exercise | M | 0.00 | 5,250 | 0 | 10,500 |